EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Potential of resveratrol in the treatment of interstitial lung disease

Rongxiu Huo, Xinxiang Huang, Yanting Yang, Yang Yang, Jinying Lin

Frontiers in Pharmacology · 06.04.2023 · 14

DOI: 10.3389/fphar.2023.1139460 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 06.04.2023. Verfasst von Rongxiu Huo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Guangxi Academy of Medical Sciences, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, C…. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interstitial lung disease (ILD) is a heterogeneous group of diseases characterized by lung injury caused by lung fibroblast proliferation, interstitial inflammation, and fibrosis. Different cell signal transduction pathways are activated in response to various proinflammatory or fibrotic cytokines, such as IL-6, and these cytokines are increased in different ILDs. The overexpressed cytokines and growth factors in ILD can activate TGF-β/Smad2/3/4, NF-κB, and JAK/STAT signal transduction pathways, promote the activation of immune cells, increase the release of pro-inflammatory and pro-fibrotic factors, differentiate fibroblasts into myofibroblasts, and promote the occurrence and development of ILD. This finding suggests the importance of signal transduction pathways in patients with ILD. Recent evidence suggests that resveratrol (RSV) attenuates excessive inflammation and pulmonary fibrosis by inhibiting the TGF-β/Smad2/3/4, NF-κB, and JAK/STAT signal transduction pathways and overactivation of immune cells. In this review, advances in lung protection and the underlying mechanisms of RSV are summarized, and the potential efficacy of RSV as a promising treatment option for ILD is highlighted.

Schlagwörter

Stichwörter der Autor:innen

adverse reactionimmune cellsinterstitial lung diseaseresveratrolsignal transduction pathway

Autor:innen und Institutionen

  • Department of Rheumatology and Immunology, Guangxi Academy of Medical Sciences, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.

Zitieren

APA

Huo, R., Huang, X., Yang, Y., Yang, Y., & Lin, J. (2023). Potential of resveratrol in the treatment of interstitial lung disease. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1139460

Vancouver

Huo R, Huang X, Yang Y, Yang Y, Lin J. Potential of resveratrol in the treatment of interstitial lung disease. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1139460

BibTeX
@article{Huo2023,
  author = {Huo, Rongxiu and Huang, Xinxiang and Yang, Yanting and Yang, Yang and Lin, Jinying},
  title = {Potential of resveratrol in the treatment of interstitial lung disease},
  journal = {Frontiers in Pharmacology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fphar.2023.1139460}
}
Kostenlos starten →